Results 31 to 40 of about 70,254 (168)
Treatment of chronic hepatitis B naïve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial). [PDF]
PLoS ONE, 2018 CONTEXT:Current drugs for chronic hepatitis B therapy have a poor efficacy in terms of post-treatment sustained viral suppression and generate important side effects during and after therapy.
Mamun Al Mahtab +8 more
doaj +1 more source
Viruses, 2021 As current interventions for chronic hepatitis B (CHB) rarely induce cure, more effective drugs are needed. Short-term treatment of woodchucks with the novel immunomodulator AIC649, a parapoxvirus-based stimulator of toll-like receptor 9 dependent and ...
Kyle E. Korolowicz +8 more
doaj +1 more source
Acta Pharmaceutica Sinica B, 2017 Although oxymatrine (OMT) has been shown to directly inhibit the replication of hepatitis B virus (HBV) in vitro, limited research has been done with this drug in vivo.
Xiuxiu Sang +14 more
doaj +1 more source
Hepatitis B e antigen-negative chronic hepatitis b in Hong Kong [PDF]
Hepatology, 2000 Hepatitis B e antigen-negative chronic hepatitis B (e−CHB) has been reported in Asia but its prevalence and clinical significance have not been determined. The aims of this study were to determine the prevalence of e−CHB in Hong Kong and the frequency of precore and core promoter mutations in these patients.
Chan, Henry L. Y. +4 more
openaire +3 more sources
Hepatitis B e Antigen–Negative Chronic Hepatitis B
TAJ: Journal of Teachers Association, 2018 Abstract not availableTAJ 2012; 25: 90 ...
DK Mohanta +8 more
openaire +2 more sources
World Journal of Gastroenterology, 2021 Quantitative hepatitis B core-related antigen (qHBcrAg) has a better correlation with intrahepatic hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) than HBV DNA or hepatitis B e antigen (HBeAg), but data are still lacking for its clinical application.The aim was to investigate serum qHBcrAg levels in patients with chronic hepatitis B and
Chi, Xiu-Mei +7 more
openaire +2 more sources
Risk of hepatocellular carcinoma in untreated patients with chronic hepatitis B: Independent of HBeAg status? [PDF]
Clinical and Molecular Hepatology, 2021 Ho Soo Chun, Minjong Lee
doaj +1 more source
Virology Journal, 2021 Background Hepatitis B virus (HBV) serum markers during typical acute self-limited infection are usually depicted as a composite of traditional HBV markers.
Mary C. Kuhns +4 more
doaj +1 more source
Viral Determinants of Hepatitis B Surface Antigen Seroclearance in Hepatitis B e Antigen–Negative Chronic Hepatitis B Patients [PDF]
The Journal of Infectious Diseases, 2011 We studied whether quantification of serum HBsAg and HBV DNA levels could predict spontaneous HBsAg clearance in patients with negative hepatitis B e antigen (HBeAg).Serum HBsAg and HBV DNA levels were measured at baseline among a longitudinal cohort of 103 HBeAg-negative patients recruited since 1997.Twelve (12%) patients developed HBsAg seroclearance
Henry Lik-Yuen, Chan +4 more
openaire +2 more sources
THE STATE OF CELL MEDIATED IMMUNITY AMONG HEPATITIS B SURFACE ,ANTGENI CARRIERS IN IRAN, [PDF]
Acta Medica Iranica, 1987 Cell-mediated immune (CMI) s t a t us and sub- popul at i ons o f pe r ipheral b l ood lymphocytes were investigated in one hundre d volunt a ry blood donors who were car r ier s of Ag • HE S A signi f i c ant decr e ase of t otal T-cells ...
A. MASSOUD
doaj +2 more sources